[Clinical features and prognosis in 49 patients with Castleman's disease]. 2009

Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
Department of Internal Medicine, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.

OBJECTIVE To analyze the clinical features and prognosis of patients with Castleman's disease (CD). METHODS Clinical and pathological data of 49 patients with CD diagnosed in Peking Union Medical College Hospital from January 1990 to December 2007 were retrospectively analyzed. RESULTS In patients with uni-centric CD (UCD), hyaline vascular type had the highest percentage (88.2%, 15/17), which was significantly higher than that of either plasma cell type (5.9%, 1/17) or mixed cell type (5.9%, 1/17) (P < 0.05). In patients with multicentric CD (MCD), there were no significant differences among the percentages of different histopathologic types. In contrast to patients with UCD, patients with MCD were relatively older and had more typical clinical features, more frequent complications, and more frequent abnormal laboratory results. Twenty patients with UCD achieved complete remission (CR) after surgery, and their complications also disappeared one month later. Twenty-three out of 29 patients with MCD were treated with chemotherapy; only 6 patients achieved CR and 9 achieved partial remission (PR), and the overall response rate was 65.2%. Two patients who initially did not responded to chemotherapy achieved CR after the addition of rituximab. CONCLUSIONS The clinical features of CD are multifarious and nonspecific, and diagnosis is exclusively depended on histopathology. UCD has a good prognosis after surgery, while MCD often poorly responds to chemotherapy and has a relatively poor prognosis. New drugs and clinical trials are needed to improve the outcome of MCD.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005871 Castleman Disease Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterized by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IMMUNOGLOBULIN A. Angiofollicular Lymphoid Hyperplasia,Castleman's Tumor,Giant Lymph Node Hyperplasia,Hyperplasia, Giant Lymph Node,Lymph Node Hyperplasia, Giant,Angiofollicular Lymph Hyperplasia,Angiofollicular Lymph Node Hyperplasia,Castleman's Disease,Castlemans Disease,Angiofollicular Lymph Hyperplasias,Angiofollicular Lymphoid Hyperplasias,Castleman Tumor,Castlemans Tumor,Disease, Castlemans,Hyperplasia, Angiofollicular Lymph,Hyperplasia, Angiofollicular Lymphoid,Lymph Hyperplasia, Angiofollicular,Lymphoid Hyperplasia, Angiofollicular,Tumor, Castleman's
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
February 2023, Zhongguo shi yan xue ye xue za zhi,
Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
October 2016, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
January 2010, Zhonghua wai ke za zhi [Chinese journal of surgery],
Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
June 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
July 2000, Anales espanoles de pediatria,
Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
January 2014, Clinical and experimental rheumatology,
Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
January 2015, Terapevticheskii arkhiv,
Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
September 2006, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery,
Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
September 2000, The Ceylon medical journal,
Guo-Pan Yu, and Shu-Jie Wang, and Jie Shi, and Yong-Qiang Zhao
October 2011, Revista de neurologia,
Copied contents to your clipboard!